(Campbell, 2007, pp. 2018 -- 2024)
Number of Claims
Independent Claims
1. The method of independent claim one wherein is: that dosages between 75 mg and 81 mg, will not have any kind of significant long-term impact on the individual.
2. The method of independent claim two wherein is: that 50% of respondents, who were given low dosages of aspirin, show little to no positive improvements in their condition.
3. The method of independent claim three wherein is: that women were more than likely, to see the positive effects from taking aspirin in comparison with men.
4. The method of the independent claim number four: is that the long-term effects of taking aspirin; will have a greater impact upon reducing the underlying levels of platelet formation in women. (Campbell, 2007, pp. 2018 -- 2024)
Dependent Claims
1. The method of claim number one wherein is: the use of aspirin therapy was first introduced by Paul Gibson in 1948. Yet, it was not until 30 years later that the benefits of taking aspirin were fully realized.
2. The method of claim number two wherein is: that LL Craven would build off of the ideas of Gibson in 1953, confirming some of the effects of using aspirin to treat coronary artery disease.
3. The method of claim number three wherein is: that there have been various studies all confirming the effectiveness of taking lower dosages of aspirin (with most recommending usage between 30mg and 130 mg).
4. The method of claim number four wherein: is that researchers found those who take dosages of 30 mg to 283 mg, saw a dramatic improvement in the underlying levels of health after a stroke.
5. The method of claim number five wherein: is that other studies have found similar effects as lower...
Healthcare -- Administration and Legal Many vectors -- science, research funding, social acceptance or rejection -- influence how and whether medical technology is eventually adopted into medical praxis (Hogle, et al., 2012). Undergirding the choices and changes is a shared body of ethical standards and law, the establishment of which is often not consensual or efficacious. Any emerging technology can encounter unanticipated social resistance and ethical concerns that can change the
PK = Deltagen Inc. PRXL = Parexel International Corp. Pvt1 = Quintiles Transnational Corp. (privately held) Industry = Biotechnology As of 2005 Source: Yahoo! Finance, April 29, 2007. Figure 1. Financial Performance: Charles River Laboratories vs. Deltagen Inc. And Parexel International Corp. - January 2002 to date. Source: Yahoo! Finance, April 29, 2007. Operating income for 2006 was reported by the company to be $188.2 million compared to $184.7 million for 2005 and its operating margin for 2006
For instance, in the eyes of the courts, an offense's level could be equated to the guideline for the seriousness of a crime. The next aspect of the scorecard was the offender's personal or associative criminal history. Prior offenses dictated a level of conviction frequencies and social offenses. Therefore the personal criminal history of an individual ends up playing a major role in the sentencing guidelines. A person's propensity
Scientific and Political Aspects of Genetically Modified Foods While there is little controversy over many aspects of biotechnology and its application, genetically modified (GM) foods have become the target of intense controversy. This controversy in the marketplace has resulted in a firestorm of public debate, scientific discussion, and media coverage. The countries most affected by this debate are Middle Eastern and third world countries, who stand to reap the benefits of solving
Role of Technology in Corporate and Social Responsibility Insider trading. The insider trading case that has become most prominent is that against Raj Rajaratnam who ran the hedgefund Galleon Group, and was charged along with his co-defendant, Danielle Chiesi, a former consultant with New Castle Funds, LLC ("Insider Trading," 2010). Rajaratnam was convicted of 14 counts of insider trading, which makes this case the largest scheme concocted by a hedge fund
Pharmaceutical industries have to operate in an environment that is highly competitive and subject to a wide variety of internal and external constraints. In recent times, there has been an increasing trend to reduce the cost of operation while competing with other companies that manufacture products that treat similar afflictions and ailments. The complexities in drug research and development and regulations have created an industry that is subject to intense
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now